AI Article Synopsis
- This study is the first phase III trial comparing trabectedin and dacarbazine in patients with advanced liposarcoma or leiomyosarcoma who have previously undergone chemotherapy.
- Patients were randomly assigned to receive either drug, with the primary focus on overall survival and secondary outcomes including progression-free survival and response duration.
- Results showed that trabectedin significantly reduced the risk of disease progression compared to dacarbazine, demonstrating better disease control in this patient population.
Article Abstract
Purpose: This multicenter study, to our knowledge, is the first phase III trial to compare trabectedin versus dacarbazine in patients with advanced liposarcoma or leiomyosarcoma after prior therapy with an anthracycline and at least one additional systemic regimen.
Patients And Methods: Patients were randomly assigned in a 2:1 ratio to receive trabectedin or dacarbazine intravenously every 3 weeks. The primary end point was overall survival (OS), secondary end points were disease control-progression-free survival (PFS), time to progression, objective response rate, and duration of response-as well as safety and patient-reported symptom scoring.
Results: A total of 518 patients were enrolled and randomly assigned to either trabectedin (n = 345) or dacarbazine (n = 173). In the final analysis of PFS, trabectedin administration resulted in a 45% reduction in the risk of disease progression or death compared with dacarbazine (median PFS for trabectedin v dacarbazine, 4.2 v 1.5 months; hazard ratio, 0.55; P < .001); benefits were observed across all preplanned subgroup analyses. The interim analysis of OS (64% censored) demonstrated a 13% reduction in risk of death in the trabectedin arm compared with dacarbazine (median OS for trabectedin v dacarbazine, 12.4 v 12.9 months; hazard ratio, 0.87; P = .37). The safety profiles were consistent with the well-characterized toxicities of both agents, and the most common grade 3 to 4 adverse effects were myelosuppression and transient elevation of transaminases in the trabectedin arm.
Conclusion: Trabectedin demonstrates superior disease control versus conventional dacarbazine in patients who have advanced liposarcoma and leiomyosarcoma after they experience failure of prior chemotherapy. Because disease control in advanced sarcomas is a clinically relevant end point, this study supports the activity of trabectedin for patients with these malignancies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070559 | PMC |
| http://dx.doi.org/10.1200/JCO.2015.62.4734 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multicellular Complex Tumor Spheroid Response to DNA Repair Inhibitors in Combination with DNA-damaging Drugs.
Cancer Res Commun
August 2023
Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland.
Unlabelled: Multicellular spheroids comprised of malignant cells, endothelial cells, and mesenchymal stem cells served as an model of human solid tumors to investigate the potentiation of DNA-damaging drugs by pharmacologic modulation of DNA repair pathways. The DNA-damaging drugs, topotecan, trabectedin, and temozolomide were combined with varied inhibitors of DNA damage response enzymes including PARP (olaparib or talazoparib), ATM (ataxia telangiectasia mutated; AZD-1390), ATR (ataxia telangiectasia and Rad3-related protein; berzosertib or elimusertib), and DNA-PK (DNA-dependent protein kinase; nedisertib or VX-984). A range of clinically achievable concentrations were tested up to the clinical , if known.
View Article and Find Full Text PDFChemotherapeutic drugs for soft tissue sarcomas: a review.
Front Pharmacol
August 2023
Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China.
Despite the low incidence of soft tissue sarcomas (STSs), hundreds of thousands of new STS cases are diagnosed annually worldwide, and approximately half of them eventually progress to advanced stages. Currently, chemotherapy is the first-line treatment for advanced STSs. There are difficulties in selecting appropriate drugs for multiline chemotherapy, or for combination treatment of different STS histological subtypes.
View Article and Find Full Text PDFEfficacy of second and third lines of treatment in advanced soft tissue sarcomas: a real-world study.
Clin Transl Oncol
December 2023
Department of Medical Oncology, La Paz University Hospital-Institute for Health Research (IdiPAZ), Paseo de la Castellana 261, 28046, Madrid, Spain.
Background: Soft tissue sarcomas (STSs) are an uncommon and heterogeneous group of tumours. Several drugs and combinations have been used in clinical practice as second-line (2L) and third-line (3L) treatment. The growth modulation index (GMI) has previously been used as an exploratory efficacy endpoint of drug activity and represents an intra-patient comparison.
View Article and Find Full Text PDFProtocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib.
BMC Cancer
March 2023
Department of Orthopaedic Surgery, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Yufu City Oita, Hasama, 879-5593, Japan.
Article Synopsis
- Soft tissue sarcomas (STS) are rare cancers treated mainly with doxorubicin-based chemotherapy as the first line, and various drugs like trabectedin, eribulin, and pazopanib are considered for second-line treatment, with no clear evidence supporting one over the others.
- The JCOG1802 study is a randomized phase II trial aimed at comparing the effectiveness of trabectedin, eribulin, and pazopanib in patients with advanced STS who have not responded to initial doxorubicin treatment.
- The study’s primary goal is to evaluate progression-free survival, while secondary goals assess overall survival and other relevant treatment outcomes in eligible participants aged 16 and older with specific STS diagnoses.
First-line chemotherapy in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis.
Cancer
August 2022
Mannheim Cancer Center, Sarcoma Unit, University of Heidelberg, Mannheim University Medical Center, Mannheim, Germany.
Background: No prospective trial with anthracycline-based chemotherapy has individually assessed response in a well-differentiated (WD)/dedifferentiated (DD) liposarcoma patient cohort. We conducted a retrospective analysis of first-line chemotherapy in liposarcoma of intra-abdominal origin (IA-LPS) in patients who had entered the European Organisation for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG) trials.
Methods: We searched for all adult patients treated with first-line chemotherapy for advanced IA-LPS in the EORTC STBSG phase 2 and 3 trials from 1978.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!